STAA Stock Risk & Deep Value Analysis
STAAR Surgical Co
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About STAA Stock
We analyzed STAAR Surgical Co using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran STAA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is STAA Stock?
Overall Risk
Moderate
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for STAA?
- ⚠
Slower than expected US adoption rates for EVO ICL
- ⚠
Negative results from competitor clinical trials or new competitive product launches
- ⚠
Increased regulatory scrutiny or adverse event reports on ICL technology
- ⚠
Broader economic slowdown impacting elective procedures
Unlock STAA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does STAAR Surgical Co (STAA) Do?
Market Cap
$1.24B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,157
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Visit STAAR Surgical Co WebsiteIs STAA Stock Undervalued?
Unlock the full AI analysis for STAA
Get the complete DVR score, risk analysis, and more
Does STAA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to extensive R&D leading to proprietary technology protected by patents, significant regulatory hurdles for new entrants, and the high switching costs associated with surgeon training and established clinical protocols for EVO ICL.
Moat Erosion Risks
- •Expiration of key patents without new innovations
- •Emergence of a superior or significantly cheaper alternative refractive surgery technology
- •Loss of regulatory approvals or new safety concerns reducing surgeon and patient confidence
STAA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive STAA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated mid-May 2026)
- •New clinical data or expanded indications for EVO ICL
- •Key opinion leader (KOL) endorsements and increased surgeon training initiatives
Medium-Term (6-18 months)
- •Acceleration in US EVO ICL procedure volume growth
- •Expanded market access and reimbursement in key international regions
- •Potential strategic partnerships for distribution or technology integration
Long-Term (18+ months)
- •EVO ICL becoming the preferred premium refractive solution over LASIK for a significant segment of the population
- •Launch of next-generation ICLs (e.g., presbyopia-correcting versions)
- •Global market share expansion leading to dominant position in implantable lens category
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for STAA?
- ✓
Quarterly acceleration in US EVO ICL unit volumes and total revenue growth
- ✓
Consistent expansion of gross margins and progress towards sustainable profitability
- ✓
Positive updates on new market entries or expanded regulatory approvals
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for STAA (STAAR Surgical Co) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
